GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guard Therapeutics International AB (OSTO:GUARD) » Definitions » Float Percentage Of Total Shares Outstanding

Guard Therapeutics International AB (OSTO:GUARD) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 21, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Guard Therapeutics International AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Guard Therapeutics International AB's float shares is 0.00 Mil. Guard Therapeutics International AB's total shares outstanding is 20.17 Mil. Guard Therapeutics International AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Guard Therapeutics International AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Guard Therapeutics International AB's Institutional Ownership is 13.70%.


Guard Therapeutics International AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Guard Therapeutics International AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/20.17
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guard Therapeutics International AB Business Description

Industry
Traded in Other Exchanges
N/A
Address
Scheelevagen 22, Lund, SWE, 223 63
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.

Guard Therapeutics International AB Headlines

No Headlines